Review article: biomarkers for predicting nucleos(t)ide analogues discontinuation and HBV recurrence after drug withdrawal in chronic hepatitis B patients
Mengqi Luo 1 , Bin Zhou 1 , Jinlin Hou 1 , Deke Jiang 1
Affiliations
Affiliation
1
State Key Laboratory of Organ Failure Research, Guangdong Key Laboratory of Viral Hepatitis Research, Institutes of Liver Diseases Research of Guangdong Province, Department of Infectious Diseases and Hepatology Unit, Southern Medical University, Nanfang Hospital, Guangzhou, China.
PMID: 35089634 DOI: 10.1111/hepr.13749
Abstract
Aim: To summarize HBV-related biomarkers predicting Nucleos(t)ide analogues (NAs) discontinuation and HBV recurrence after drug withdrawal in chronic hepatitis B (CHB) patients, providing references for clinical medication, so as to manage CHB patients more scientifically.
Methods: Related pieces of literature were retrieved in PubMed and the results were sorted out. We then analyzed and summarised these articles.
Results: We found that HBV related biomarkers maybe could predict NAs withdrawal safely and the possibility of relapse after treatment cessation, including hepatitis B e antigen (HBeAg), hepatitis B surface antigen (HBsAg), HBV DNA, HBV RNA, pregenomic-RNA (pgRNA), hepatitis B core-related antigen (HBcrAg), hepatitis B core antibody (anti-HBc), and models containing several indicators for predicting the effectiveness of treatment.
Conclusions: HBV DNA, HBV RNA, pgRNA, HBcrAg, anti-HBc, as well as the prediction models formed by several biomarkers could predict the safe discontinuation of NAs before HBsAg loss and recurrence. This article is protected by copyright. All rights reserved.